New PET scan may predict immunotherapy success in melanoma

NCT ID NCT05289193

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times

Summary

This study tests whether giving a combination of two immunotherapy drugs (nivolumab and ipilimumab) before surgery can shrink melanoma tumors and prevent the cancer from coming back. About 28 adults with stage III melanoma that can be surgically removed will receive the drugs before their operation. The study also uses an experimental PET scan to image immune cells, aiming to see if the scan can predict how well the treatment works.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.